Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Total positions of BlackRock, Inc. and its funds subject to notification:ORION CORPORATION
STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS
25 APRIL 2024 at 16.30 EEST
ORION CORPORATION
交易所公告 - 主要股东公告
2024年4月25日，东欧夏令时下午4:30
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
Orion Corporation：根据《证券市场法》第9章第10条的披露(BlackRock, Inc.)
Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds increased on 24 April 2024 above five (5) per cent of Orion Corporation's total shares.
根据《证券市场法》第9章第5条的披露，BlackRock、Inc.及其所有基金直接、间接持有公司股份并通过金融工具增持公司股份，使其持有公司总股份达到5%以上。
Total positions of BlackRock, Inc. and its funds subject to notification:
BlackRock, Inc.及其所有基金需要通报的总持股仓位：
|
% of shares and voting rights (total of point A) |
% of shares and voting rights through financial instruments (total of point B) |
Total of both in % (points A + B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 4.99% shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
5.01% shares Below 5% voting rights |
141,134,278 shares 772,549,137 voting rights |
| Position of previous notification (if applicable) | Below 5% shares Below 5% voting rights |
Below 5% shares Below 5% voting rights |
Below 5% shares Below 5% voting rights |
| 股份和表决权的百分比(点A的总和) 股份和表决权的百分比(点A的总和) |
通过金融工具持有的股份和表决权的百分比(点B的总和) 通过金融工具持有的股份和表决权的百分比(点B的总和) |
两点合总百分比(A点+B点) | 发行人的股票和表决权总数 | |
| 达到或超过门槛的日期形成的情况 | 4.99%的股份 持有投票权低于5% |
0.02%的股份 持有投票权低于5% |
5.01%的股份 持有投票权低于5% |
141,134,278股 772,549,137表决权 |
| 上次通知的位置（如适用） | 持有股份低于5% 持股不超过5%的表决权 |
持股不超过5%的股份 持表决权不超过5% |
持股不超过5%的股份 持表决权不超过5% |
Notified details of the resulting situation on the date on which the threshold was crossed:
于阈值被突破当天通报的相关情况如下：
Point A: Shares and voting rights:
A点：股份和表决权：
|
Class/type of shares ISIN code |
Number of shares and voting rights | % of shares and voting rights | ||
| Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI0009014377 | 7,042,654 shares Below 5% voting rights |
4.99% shares Below 5% voting rights |
||
| POINT A SUBTOTAL | 7,042,654 shares Below 5% voting rights |
4.99% shares Below 5% voting rights |
||
| 股票类别/类型 国际证券识别码（ISIN） |
股份和表决权的数量 | 股份数量和表决权的百分比 | ||
| 直接（SMA 9：5） | 间接（SMA 9：6和9：7） | 直接（SMA 9：5） | 间接（SMA 9：6和9：7） | |
| FI0009014377 | 7,042,654股份 持表决权不超过5% |
持股不超过4.99%的股份 持表决权不超过5% |
||
| A点小计 | 7,042,654股份 持表决权不超过5% |
持股不超过4.99%的股份 持表决权不超过5% |
||
Point B: Financial instruments according to SMA 9:6a:
B点：依据SMA 9:6a规定的金融工具：
| Type of financial instrument | Expiration date | Exercise / Conversion Period | Physical or cash settlement | Number of shares and voting rights | % of shares and voting rights |
| Securities Lent | N/A | N/A | Physical | 34,596 shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
| CFD | N/A | N/A | Cash | 4,438 shares Below 5% voting rights |
0.00% shares Below 5% voting rights |
| POINT B SUBTOTAL | 39,034 shares Below 5% voting rights |
0.02% shares Below 5% voting rights |
| 金融工具类型 | 到期日 | 行使/转换期 | 实物或现金结算 | 股份和表决权的数量 | 股份数量和表决权的百分比 |
| 证券借贷 | 无数据 | 无数据 | 物理占用 | 34,596股份 持有不超过5%的表决权 |
0.02%的股份 持有不超过5%的表决权 |
| 价差合约 | 无数据 | 无数据 | 现金 | 4,438股份 持有不超过5%的表决权 |
0.00%的股份 持有不超过5%的表决权 |
| POINt b 小计 | 39,034股份 持有不超过5%的表决权 |
0.02%的股份 持有不超过5%的表决权 |
Orion Corporation
Orion公司
| Liisa Hurme President and CEO |
Olli Huotari SVP, Corporate Functions |
| Liisa Hurme 总裁和首席执行官 |
Olli Huotari 高级副总裁，企业职能 |
Contact person:
Tuukka Hirvonen, Investor Relations
联系人：
投资者关系，Tuukka Hirvonen，电话：+358 10 426 2721
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
出版商：
Orion公司
通信-半导体
Orionintie 1A, 芬兰Espoo, 邮编：FI-02200
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Orion是一家在全球范围内运营的芬兰制药公司,致力于创造健康。我们开发、制造和销售人类和兽医药品以及活性药品成分。Orion拥有广泛的专有和通用药品和消费品，我们的药品研发的核心治疗领域是肿瘤学和疼痛学。Orion开发的专有产品用于治疗癌症、神经系统疾病和呼吸系统疾病，等等。2023年，Orion的净销售额为11.9亿欧元，公司年底有大约3,600名员工。Orion的A股和B股在赫尔辛基纳斯达克股票交易所上市。
